The Chalcogen, X, Is In A -c(=x)- Group Patents (Class 548/204)
-
Publication number: 20090291952Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: ApplicationFiled: July 6, 2007Publication date: November 26, 2009Applicant: GILEAD SCIENCES, INC.Inventors: Manoj C. Desai, Allen Y. Hong, Hongtao Liu, Randall W. Vivian, Lianhong Xu
-
Patent number: 7622593Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.Type: GrantFiled: June 26, 2007Date of Patent: November 24, 2009Assignee: The Procter & Gamble CompanyInventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
-
Publication number: 20090286792Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.Type: ApplicationFiled: November 19, 2008Publication date: November 19, 2009Inventors: Chu-Biao Xue, Brian W. Metcalf, Amy Qi Han, Darius J. Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
-
Publication number: 20090275621Abstract: The present invention is directed to 1,3,4-oxadiazalones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.Type: ApplicationFiled: July 20, 2009Publication date: November 5, 2009Applicants: AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Daniel G. MCGARRY, Jochen GOERLITZER, Stefanie KEIL, Karen CHANDROSS, Jean MERRILL, Wolfgang WENDLER
-
Publication number: 20090253705Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: ApplicationFiled: April 2, 2009Publication date: October 8, 2009Inventors: Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Sookhee Nicole Ha, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Dong-Ming Shen, Liping Wang, Cheng Zhu
-
Patent number: 7598250Abstract: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is X is —O—, —C(R14)2— or —N(R)—; Z is —C(R14)2— or —N(R)—; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR35, —N(R24)(R25) or —SR35; R41 is alkyl, cycloalkyl, —SO2(alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I.Type: GrantFiled: August 4, 2004Date of Patent: October 6, 2009Assignee: Schering CorporationInventors: Jared N. Cumming, Ying Huang, Guoqing Li, Ulrich Iserloh, Andrew Stamford, Corey Strickland, Johannes H. Voigt, Yusheng Wu, Jianping Pan, Tao Guo, Douglas W. Hobbs, Thuy X. H. Le, Jeffrey F. Lowrie
-
Publication number: 20090240052Abstract: An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substituted phenyl, a monocyclic heterocyclic group, etc.; X1 represents carbonyl, etc.; X2 represents optionally substituted alkylene group, a bond, etc.; X3 represents oxygen, a bond, etc.; and X4 represents a group represented by the general formula -X5-X6- or -X6-X5- (wherein X5 means oxygen, a bond, etc.; and X6 means optionally substituted alkylene, a bond, etc.)] or a salt of the derivative. The derivative or salt has the inhibitory activity of MMP-13 production and is hence useful as a therapeutic agent for articular rheumatism, osteoarthritis, cancer, etc.Type: ApplicationFiled: December 6, 2005Publication date: September 24, 2009Applicant: Toyama Chemical Co., Ltd.Inventors: Junichi Yokotani, Yoichi Taniguchi, Eiji Hara, Hitoshi Akitsu, Yukie Tada
-
Publication number: 20090227603Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification.Type: ApplicationFiled: February 23, 2009Publication date: September 10, 2009Inventors: Romyr Dominique, Robert Alan Goodnow, JR., Agnieszka Kowalczyk, Jianping Lou, Qi Qiao, Achyutharao Siddurl, Jefferson Wright Tilley
-
Publication number: 20090227643Abstract: The present invention relates to 5-membered azacycle compounds of formula (I), pharmaceutically acceptable salts thereof and hydrates thereof, wherein the groups are as defined in the specification. The present invention further relates to pharmaceutical compositions containing said compounds or pharmaceutically acceptable salts thereof or hydrates thereof, and to use of the pharmaceutical compositions in (i) improving skin elasticity or reducing skin wrinkles, (ii) treating diabetes, (iii) treating or relieving adverse sequelae of diabetes, (iv) treating or relieving kidney damage, (v) treating or relieving damage to blood vasculature, (vi) treating or relieving hypertension, (vii) treating or relieving retinopathy, (viii) treating or relieving damage to lens proteins, (ix) treating or relieving cataract, (x) treating or relieving peripheral neuropathy, or (xi) treating or relieving osteoarthritis.Type: ApplicationFiled: January 29, 2007Publication date: September 10, 2009Applicant: BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Song Li, Hao Cui, Junhai Xiao, Wu Zhong, Lili Wang, Gang Cheng
-
Publication number: 20090221574Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.Type: ApplicationFiled: November 3, 2006Publication date: September 3, 2009Applicant: AMIRA PHARMACEUTICALS, INC.Inventors: John H. Hutchinson, Petpiboon Peppi Prasit, Mark Moran, Jillian F. Evans, Yiwei Li, Jasmine Eleanor Zunic, Mustapha Haddach, Nicholas Simon Stock
-
Publication number: 20090209588Abstract: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.Type: ApplicationFiled: May 3, 2005Publication date: August 20, 2009Applicant: Novo Nordisk A/SInventors: Miroslav Havranek, Per Sauerberg, Ingrid Pettersson, Pavel Pihera, Søren Ebdrup
-
Publication number: 20090209533Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.Type: ApplicationFiled: February 13, 2009Publication date: August 20, 2009Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Elfatih Elzein, Tetsuya Kobayashi, Rao Kalla, Thao Perry, Xiaofen Li, Robert Jiang, Ivan Diamond, Lina Yao, Peidong Fan, Maria Pia Arolfo, Zhan Jiang, Wing Ming Keung, Guoxin Tao
-
Patent number: 7569698Abstract: The invention relates to a desorption process for epothilones, especially epothilone A and/or epothilone B, from resins and new production, work-up or purification processes or manufacturing methods for epothilones comprising said desorption process, as well as the use of certain solvents for the desorption of epothilones from resins.Type: GrantFiled: August 17, 2005Date of Patent: August 4, 2009Assignee: Novartis AGInventors: Ernst Kuesters, Heinz Unternaehrer
-
Publication number: 20090192151Abstract: Disclosed herein are compounds useful in treating glaucoma, inflammatory bowel disease, the stimulation of hair growth, and the stimulation of the conversion of vellus hair to terminal hair. The compounds themselves are herein.Type: ApplicationFiled: January 14, 2009Publication date: July 30, 2009Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090192175Abstract: Novel heteroaromatic compounds of formula (I): wherein A1, A2, A3, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.Type: ApplicationFiled: April 25, 2007Publication date: July 30, 2009Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Pierre Jung, Patricia Durieux, William Lutz, Peter Maienfisch, Thomas Pitterna, Peter Renold, Werner Zambach
-
Publication number: 20090192203Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.Type: ApplicationFiled: November 7, 2006Publication date: July 30, 2009Applicant: IRM LLCInventors: Robert Epple, Christopher Cow, Mihai Azimioara, Ross Russo, Yongping Xie, Xing Wang
-
Patent number: 7566730Abstract: The invention provides compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.Type: GrantFiled: September 10, 2003Date of Patent: July 28, 2009Assignee: Elan Pharmaceuticals, Inc.Inventors: James P. Beck, Matthew Drowns, Martha A. Warpehoski
-
Publication number: 20090186868Abstract: A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or an alkoxy group, R3 represents hydrogen atom, a halogen atom, hydroxyl group, or an alkoxy group, R4 represents hydrogen atom, or an alkyl group, Z1 and Z2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, Z3 represents cyano group, an alkyl group, an alkenyl group and the like, Z4 represents an alkyl group, an alkenyl group, an alkynyl group and the like, and represents a single bond or a double bond], which shows high antitumor effect against cancer cells including drug resistant cells.Type: ApplicationFiled: October 24, 2006Publication date: July 23, 2009Applicant: Daiichi Sankyo Company LimitedInventors: Kouichi Uoto, Yasuyuki Takeda, Atsunobu Sakamoto, Yoshihiro Takayanagi
-
Patent number: 7563902Abstract: The present invention relates to novel chemiluminescent compounds, to a method for synthesizing these compounds, to derivatives and conjugates comprising these compounds, to the use of these compounds or conjugates thereof in chemiluminescence based assays, especially in immunoassays.Type: GrantFiled: January 25, 2006Date of Patent: July 21, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Dieter Heindl, Rupert Herrmann, Wolfgang Jenni
-
Publication number: 20090181902Abstract: The present application provides for a compound of Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: ApplicationFiled: July 3, 2008Publication date: July 16, 2009Applicant: Gilead Sciences,Inc.Inventors: Manoj C. Desai, Hon C. Hui, Hongtao Liu, Jianyu Sun, Lianhong Xu
-
Publication number: 20090176822Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4?, R5, R6 and R6? are as described herein.Type: ApplicationFiled: April 17, 2008Publication date: July 9, 2009Applicant: Genentech, Inc.Inventors: Frederick Cohen, Vickie Hsiao-Wei Tsui, Cuong Ly, John A. Flygare
-
Publication number: 20090175820Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: ApplicationFiled: December 19, 2008Publication date: July 9, 2009Applicant: Gilead Sciences, Inc.Inventors: Manoj C. Desai, Hon C. Hui, Hongtao Liu, Lianhong Xu
-
Publication number: 20090170172Abstract: Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.Type: ApplicationFiled: October 31, 2007Publication date: July 2, 2009Applicant: Kosan Biosciences, Inc.Inventors: Bryan Julien, Leonard Katz, Chaitan Khosla, Li Tang, Rainer Ziermann
-
Patent number: 7553859Abstract: The present invention relates to new Macro-cycles of Formula (I), and their use for the treatment of cancer.Type: GrantFiled: July 15, 2003Date of Patent: June 30, 2009Assignees: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)Inventors: Gerhard Hoefle, Wolfgang Richter
-
Publication number: 20090156651Abstract: A compound of general formula (I): A process for preparing this compound. A fungicide composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it.Type: ApplicationFiled: April 6, 2006Publication date: June 18, 2009Inventors: Darren Mansfield, Pierre-Yves Coqueron, Philippe Desbordes, Heiko Rieck, Alain Villier, Pierre Genix, Marie-Claire Grosjean-Cournoyer
-
Patent number: 7547701Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: September 17, 2004Date of Patent: June 16, 2009Assignee: Virobay, Inc.Inventors: John O. Link, Craig J. Mossman, Soon H. Woo, Sheila M. Zipfel
-
Publication number: 20090149516Abstract: The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).Type: ApplicationFiled: June 9, 2008Publication date: June 11, 2009Inventors: Samuel J. Danishefsky, Alexey Rivkin, Fumihiko Yoshimura, Ting-Chao Chou, Ana E. Gabarda, Huajin Dong, Kaida Wu, Malcolm A.S. Moore, David Dorn
-
Publication number: 20090149509Abstract: N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, salts or prodrugs thereof have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by PDF inhibitors, such as treatment of bacterial infections.Type: ApplicationFiled: December 3, 2008Publication date: June 11, 2009Applicant: VICURON PHARMACEUTICALS INC.Inventors: Jeffrey JACOBS, Rakesh K. JAIN, Jason G. LEWIS, Dinesh V. PATEL, Zhengyu YUAN
-
Patent number: 7541472Abstract: Compounds of formula I are described: along with compositions thereof, methods of use thereof (particularly as fungicides), and methods of making the same.Type: GrantFiled: May 24, 2005Date of Patent: June 2, 2009Assignee: Cropsolution, Inc.Inventors: Richard Anderson, Shy-Fuy Lee, Vivian Du, Takeo Hokama, Rafael Oey, Patricia Arakaki
-
Publication number: 20090136431Abstract: The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I) as described above.Type: ApplicationFiled: November 6, 2006Publication date: May 28, 2009Applicant: ORCHID RESEARCH LABORATORIES LIMITEDInventors: Akella S.S.V. Srinivas, Urkalan K. Balan, Narayana S. Punthalir, Rama S. Velmurugan, Sriram Rajagopal, Gaddam O. Reddy, Virendra Kachhadia
-
Publication number: 20090137548Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.Type: ApplicationFiled: December 29, 2006Publication date: May 28, 2009Inventors: Amjad Ali, Zhijian Lu, Peter J. Sinclair, Yi-Heng Chen, Cameron J. Smith, Hong Li
-
Publication number: 20090131384Abstract: The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.Type: ApplicationFiled: March 22, 2007Publication date: May 21, 2009Applicant: SYNDEXA PHARMACEUTICALS CORPORATIONInventors: Teoman Uysal, Nicholas D.P. Cosford
-
Publication number: 20090124671Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.Type: ApplicationFiled: October 23, 2008Publication date: May 14, 2009Applicant: ABBOTT LABORATORIESInventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
-
Publication number: 20090118160Abstract: Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.Type: ApplicationFiled: January 6, 2009Publication date: May 7, 2009Inventors: Andrew Thomas Bach, Prasad Koteswara Kapa, George Tien-San Lee, Eric M. Loeser, Michael Lloyd Sabio, James Lawrence Stanton, Thalaththani Ralalage Vedananda
-
Publication number: 20090118516Abstract: The present invention provides a process for preparing thiazole derivatives of formula (I), that activate the delta subtype of the human Peroxisome Proliferator Activated Receptor (hPPAR ?), and also provides compounds of formula (II), (IV), (X), (XI) and (XII), intermediate compounds for preparation of the above compounds of formula (I).Type: ApplicationFiled: May 7, 2005Publication date: May 7, 2009Inventors: Heon Joong Kang, Jung Yeob Ham
-
Publication number: 20090111803Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF—or combinations thereof.Type: ApplicationFiled: December 18, 2008Publication date: April 30, 2009Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K.C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankat
-
Publication number: 20090105257Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.Type: ApplicationFiled: November 15, 2004Publication date: April 23, 2009Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, JR.
-
Publication number: 20090105279Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 19, 2007Publication date: April 23, 2009Inventors: Carina E. Cannizzaro, James M. Chen, Manoj C. Desai, Michael L. Mitchell, Sundaramoorthi Swaminathan, Lianhong Xu, Zheng-Yu Yang
-
Publication number: 20090088452Abstract: The present invention is directed to substituted indole compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: November 17, 2006Publication date: April 2, 2009Inventors: Paul J. Coleman, Anthony J. Roecker, Jeffrey M. Bergman
-
Publication number: 20090076100Abstract: The present application describes deuterium-enriched GSK625433, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Patent number: 7504420Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.Type: GrantFiled: August 9, 2006Date of Patent: March 17, 2009Assignees: CoMentis, Inc., The Board of Trustees of the University of Illinois, Oklahoma Medical Research Foundation, Purdue Research FoundationInventors: Arun K. Ghosh, Nagaswamy Kumaragurubaran, Chunfeng Liu, Thippeswamy Devasamudram, Hui Lei, Lisa M. Swanson, Sudha V. Ankala, Jordan J. N. Tang, Geoffrey M. Bilcer
-
Publication number: 20090062269Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: February 2, 2007Publication date: March 5, 2009Inventors: Subharekha Raghavan, Darby Rye Schmidt, Steven L. Colletti, Abigail Lee Smenton
-
Publication number: 20090054423Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: April 7, 2006Publication date: February 26, 2009Inventors: Jason E. Imbriglio, Steven L. Colletti, James R. Tata, Rui Liang, Subharekha Raghavan, Darby R. Schmidt, Abigail L. Smenton, Sook Yee Chan
-
Publication number: 20090054448Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or stereoisomers thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.Type: ApplicationFiled: September 5, 2006Publication date: February 26, 2009Inventor: Philip Jones
-
Publication number: 20090047687Abstract: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.Type: ApplicationFiled: March 31, 2008Publication date: February 19, 2009Inventors: Derek B. Lowe, Philip L. Wickens, Xin Ma, Mingbao Zhang, William H. Bullock, Philip D. G. Coish, Ingo A. Mugge, Andreas Stolle, Ming Wang, Yamin Wang, Chengzhi Zhang, Hai-Jun Zhang, Lei Zhu, Manami Tsutsumi, James N. Livingston
-
Publication number: 20090048225Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.Type: ApplicationFiled: August 15, 2005Publication date: February 19, 2009Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
-
Publication number: 20090042867Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1 to R13, A, B, L, and i are defined as indicated in the description and the claims, as well as the use thereof for treating Alzheimer's disease (AD) and similar diseases.Type: ApplicationFiled: August 8, 2006Publication date: February 12, 2009Inventors: Klaus Fuchs, Christian Eickmeier, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
-
Publication number: 20090042926Abstract: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: December 20, 2006Publication date: February 12, 2009Inventors: Jason Imbriglio, Steven L. Colletti, James R. Tata, Richard T. Beresis, Daria Marley, Subharekha Raghavan, Darby Rye Schmidt, Ashley Rouse Lins, Abigail L. Smenton, Weichun Chen, Hong Shen, Fa-Xiang Ding, Rena Bodner
-
Publication number: 20090036450Abstract: The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.Type: ApplicationFiled: November 20, 2007Publication date: February 5, 2009Applicant: JAPAN TOBACCO, INC.Inventors: Masaki Takagi, Takeshi Nakamura, Isamu Matsuda, Toshihiro Kiguchi, Naoki Ogawa, Hidekazu Ozeki
-
Publication number: 20090029995Abstract: This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.Type: ApplicationFiled: November 29, 2006Publication date: January 29, 2009Applicants: WARNER-LAMBERT COMPANY, WARNER-LAMBERT COMPANY LLCInventors: Amy Mae Bunker, Mark Anthony Morris, Patrick Michael O'Brien, Michael William Wilson